Ultrasound-Guided High-Intensity Focused Ultrasound Combined With PD-1 Blockade in Patients With Liver Metastases From Lung Cancer: Protocol for a Single-Arm Phase 2 Trial DOI Creative Commons

Chao Hu,

Qiang Fu,

Fei Gao

et al.

JMIR Research Protocols, Journal Year: 2024, Volume and Issue: 13, P. e59152 - e59152

Published: Nov. 29, 2024

Background While immunotherapy has revolutionized oncological management, its efficacy in lung cancer patients with liver metastases remains limited, potentially due to the unique immunosuppressive microenvironment of liver. Local treatment been shown enhance response, and high-intensity focused ultrasound (HIFU), a minimally invasive local treatment, demonstrated promising results combination immunotherapy. However, clinical data regarding HIFU are limited. Objective We designed HILL (Ultrasound-Guided High-Intensity Focused Ultrasound Combined With PD-1 Blockade Patients Liver Metastases From Lung Cancer) study investigate effectiveness safety for metastases. Methods The is single-armed, single-center, phase 2 trial that will enroll 30 regimen involves administering 1 week before first dose programmed cell death protein (PD)–1 blockade, which then administered every 3 weeks. primary aim determine overall response rate based on immune-related criteria. Secondary aims include safety, progression-free survival, quality life. Exploratory studies also be conducted using whole blood, plasma, archival tissue, tumor biopsies during progression or relapse identify potential biomarkers. Results was funded March 14, 2022, received ethical approval April 27, 2022. Clinical registration completed by June 10, participant recruitment beginning July Data collection commenced enrollment patient. By 2024, 6 participants had recruited. expected published December 2026. Conclusions This seeks improve outcomes combining inhibition. biomarkers through exploratory research can aid selecting optimized future. Trial Registration Chinese Registry ChiCTR2200061076; https://www.chictr.org.cn/showproj.html?proj=170967 International Registered Report Identifier (IRRID) DERR1-10.2196/59152

Language: Английский

High‑intensity focused ultrasound thermal ablation boosts the efficacy of immune checkpoint inhibitors in advanced cancers with liver metastases: A single‑center retrospective cohort study DOI Open Access
Yao Liao, Decai Wang,

Xiyue Yang

et al.

Oncology Letters, Journal Year: 2025, Volume and Issue: 29(3)

Published: Jan. 7, 2025

High-intensity focused ultrasound thermal ablation (HIFU) is a novel non-invasive technique in the treatment of liver metastases (LIM) that allows focal destruction and not affected by dose limits. This retrospective study aimed to explore efficacy HIFU improving survival safety method newly diagnosed patients with cancer LIM who received first-line immune checkpoint inhibitor (ICI) therapy. Between January 2018 December 2023, data from 438 were treated at Mianyang Central Hospital (Mianyang, China) reviewed. A total 94 enrolled this study, whom 28 lung carcinoma, 36 gastric 11 esophageal 7 cholangiocarcinoma 12 other malignancies. The divided into groups depending on whether they underwent HIFU. Progression-free (PFS), overall (OS) adverse events (AEs) compared. Clinicopathological features analyzed using chi-squared test. Of patients, ICI + as treatment. After median follow-up 13.8 months, PFS OS group 2.38 times [10.95 vs. 4.60 95% confidence interval (CI): 1.087-3.106, P<0.0001] 1.84 (19.6 10.67 CI: P=0.0418), respectively, higher than without All-cause AEs immune-mediated similar between However, incidence grade 1-2 AEs, troponin elevation, hepatotoxicity renal dysfunction more common current those reported previously for entire population. No ≥3 occurred either group. prolonged advanced LIM, manageable tolerability. plan undergo warrants further prospective clinical investigation.

Language: Английский

Citations

0
A Study on the Efficacy and Safety of High-Intensity Focused Ultrasound Treatment for Colorectal Cancer Liver Metastases DOI

严方 许

Advances in Clinical Medicine, Journal Year: 2025, Volume and Issue: 15(01), P. 2131 - 2140

Published: Jan. 1, 2025

Language: Английский

Citations

0
Application of combined ablation and immunotherapy in NSCLC and liver cancer: Current status and future prospects DOI Creative Commons

Jingshun Zhang,

Yuan-dong Sun,

Yuanmin Li

et al.

Heliyon, Journal Year: 2024, Volume and Issue: 10(16), P. e36388 - e36388

Published: Aug. 1, 2024

Language: Английский

Citations

0
Ultrasound-Guided High-Intensity Focused Ultrasound Combined With PD-1 Blockade in Patients With Liver Metastases From Lung Cancer: Protocol for a Single-Arm Phase 2 Trial DOI Creative Commons

Chao Hu,

Qiang Fu,

Fei Gao

et al.

JMIR Research Protocols, Journal Year: 2024, Volume and Issue: 13, P. e59152 - e59152

Published: Nov. 29, 2024

Background While immunotherapy has revolutionized oncological management, its efficacy in lung cancer patients with liver metastases remains limited, potentially due to the unique immunosuppressive microenvironment of liver. Local treatment been shown enhance response, and high-intensity focused ultrasound (HIFU), a minimally invasive local treatment, demonstrated promising results combination immunotherapy. However, clinical data regarding HIFU are limited. Objective We designed HILL (Ultrasound-Guided High-Intensity Focused Ultrasound Combined With PD-1 Blockade Patients Liver Metastases From Lung Cancer) study investigate effectiveness safety for metastases. Methods The is single-armed, single-center, phase 2 trial that will enroll 30 regimen involves administering 1 week before first dose programmed cell death protein (PD)–1 blockade, which then administered every 3 weeks. primary aim determine overall response rate based on immune-related criteria. Secondary aims include safety, progression-free survival, quality life. Exploratory studies also be conducted using whole blood, plasma, archival tissue, tumor biopsies during progression or relapse identify potential biomarkers. Results was funded March 14, 2022, received ethical approval April 27, 2022. Clinical registration completed by June 10, participant recruitment beginning July Data collection commenced enrollment patient. By 2024, 6 participants had recruited. expected published December 2026. Conclusions This seeks improve outcomes combining inhibition. biomarkers through exploratory research can aid selecting optimized future. Trial Registration Chinese Registry ChiCTR2200061076; https://www.chictr.org.cn/showproj.html?proj=170967 International Registered Report Identifier (IRRID) DERR1-10.2196/59152

Language: Английский

Citations

0